^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
221 Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
Published date:
11/03/2022
Excerpt:
ORR and CRc rates for TP53 wild-type vs TP53 mutant was 68% and 14%, vs 64% and 14%....In conclusion, this regimen is associated with deep remissions and a high rate of transition to transplant inpatients with R/R AML, particularly in TP53 wild-type.
Secondary therapy:
FLAG-IDA
DOI:
https://doi.org/10.1182/blood-2022-164922
Source:
Title:
Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine
Published date:
08/25/2022
Excerpt:
For poor-risk cytogenetics+TP53wt, venetoclax+azacitidine vs. azacitidine alone resulted in composite remission rates (CRc) of 70% vs. 23%, median DoR of 18.4 vs. 8.5 months, and median OS of 23.4 vs. 11.3 months, respectively….However,in poor-risk cytogenetics+TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable to similarly-treated patients with intermediate-risk cytogenetics.
DOI:
10.1158/1078-0432.CCR-22-1183
